Receptor-selective retinoids for psoriasis: Focus on tazarotene

American Journal of Clinical Dermatology

Volumn 7, Issue 2, 2006, Pages 85-97

  Weindl, Günther ^a   Roeder, Alexander ^b   Schäfer Korting, Monika ^c   Schaller, Martin ^a   Korting, Hans Christian ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ANTIPSORIASIS AGENT; BETAMETHASONE DIPROPIONATE; BEXAROTENE; BIOLOGICAL PRODUCT; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; DIFLORASONE DIACETATE; ETHINYLESTRADIOL; ETRETIN; ETRETINATE; FENRETINIDE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; FLUTICASONE PROPIONATE; INTERFERON; ISOTRETINOIN; METHOTREXATE; MOMETASONE FUROATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PSORALEN; RETINOIC ACID; RETINOID; TACALCITOL; TAZAROTENE;

ACUTE TOXICITY; AGING; ALOPECIA; ANEMIA; APPLICATION SITE REACTION; ARTHRALGIA; ARTHROPATHY; BACKACHE; BASAL CELL CARCINOMA; BURNING SENSATION; CHEILITIS; CHEMOTHERAPY INDUCED EMESIS; CHRONIC TOXICITY; CLINICAL TRIAL; DESQUAMATION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DRY NOSE; DRY SKIN; ERYTHEMA; FLU LIKE SYNDROME; FOOT PAIN; HEADACHE; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; HYPESTHESIA; HYPOTHYROIDISM; INFECTION; KIDNEY INJURY; LETHARGY; LEUKOPENIA; LIGAMENT CALCINOSIS; LIVER CIRRHOSIS; LIVER TOXICITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MYALGIA; NAUSEA; ONYCHOLYSIS; OSTEOPHYTE; PARESTHESIA; PHOTOSENSITIVITY; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; RASH; RETINOL INTOXICATION; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SKIN IRRITATION; SKIN PAIN; STOMATITIS; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; NICOTINIC ACIDS; PSORIASIS; RECEPTORS, RETINOIC ACID; RETINOIDS;

EID: 33645859890     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200607020-00002     Document Type: Review

References (67)

1. Lee CS, Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother 2005 Aug; 6 (10): 1725-34
2. Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 2004 Feb; 50 (2): 301-9
3. Ho VC. The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol 2004 May; 150 Suppl. 67: 1-10
4. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003 Oct; 25 (10): 2487-505
5. Allergan, Inc. Allergan receives written response from FDA on oral tazarotene [online]. Available from URL: http://www.shareholder.com/agn/ReleaseDetail.cfm?ReleaseID=164878 [Accessed 2006 Mar 20]
6. Trends-in-Medicine. FDA's Dermatologic and Ophthalmic Drugs Advisory Committee meeting on Allergan's Tazoral for moderate-to-severe psoriasis; Gaithersburg, Maryland; July 12, 2004. [online]. Available from URL: http://www.trends-in-medicine.com/July2004/FDAtazoral074p.pdf [Accessed 2006 Mar 20]
7. Van Zander J, Orlow SJ. Efficacy and safety of oral retinoids in psoriasis. Expert Opin Drug Saf 2005; 4 (1): 129-38
8. Dando TM, Wellington K. Topical tazarotene: a review of its use in the treatment of plaque psoriasis. Am J Clin Dermatol 2005; 6 (4): 255-72
9. Nagpal S, Chandraratna RA. Recent developments in receptor-selective retinoids. Curr Pharm Des 2000 Jun; 6 (9): 919-31
10. Fisher GJ, Talwar HS, Xiao JH, et al. Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem 1994 Aug 12; 269 (32): 20629-35
11. Lefebvre P. Molecular basis for designing selective modulators of retinoic acid receptor transcriptional activities. Curr Drug Targets Immune Endocr Metabol Disord 2001 Aug; 1 (2): 153-64
12. Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999 Oct; 37 (4): 273-87
13. Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem 1995 Jan 13; 270 (2): 923-7
14. Love JM, Gudas LJ. Vitamin A, differentiation and cancer. Curr Opin Cell Biol 1994 Dec; 6 (6): 825-31
15. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996 May 3; 85: 403-14
16. Liu PT, Krutzik SR, Kim J, et al. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005 Mar 1; 174: 2467-70
17. Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1994 Apr; 30: 581-90
18. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002 Jan; 41: 41-55
19. Niles RM. The use of retinoids in the prevention and treatment of skin cancer. Expert Opin Pharmacother 2002 Mar; 3: 299-303
20. Nagpal S, Patel S, Asano AT, et al. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J Invest Dermatol 1996 Feb; 106: 269-74
21. Nagpal S, Patel S, Jacobe H, et al. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol 1997 Jul; 109: 91-5
22. DiSepio D, Ghosn C, Eckert RL, et al. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci U S A 1998 Dec 8; 95: 14811-5
23. Orlandi A, Bianchi L, Costanzo A, et al. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. J Invest Dermatol 2004 Apr; 122: 1037-41
24. Bianchi L, Orlandi A, Campione E, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol 2004 Jul; 151: 148-56
25. Papoutsaki M, Lanza M, Marinari B, et al. The p73 gene is an anti-tumoral target of the RARbeta/gamma-selective retinoid tazarotene. J Invest Dermatol 2004 Dec; 123: 1162-8
26. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997 Jul; 37: 85-92
27. Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003 May; 48: 760-7
28. Allergan, Inc. Tazoral™ for the treatment of moderate to very severe plaque psoriasis: briefing document prepared by Allergan for the Dermatologic and Ophthalmic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee meeting [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4062B1_01_Allergan- Background.pdf [Accessed 2006 Mar 13]
29. Attar M, Yu D, Ni J, et al. Disposition and biotransformation of the acetylenic retinoid tazarotene in humans. J Pharm Sci 2005; 94 (10): 2246-55
30. Yu Z, Yu D, Walker PS, et al. Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. Clin Pharmacokinet 2004; 43: 673-84
31. Krueger GG, Drake LA, Elias PM, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998 Jan; 134: 57-60
32. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001 Nov; 68: 355-8
33. Bianchi L, Soda R, Diluvio L, et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 2003 Jul; 149: 207-9
34. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 39 (4 Pt 1): 590-6
35. Gollnick H, Menter A. Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999 Apr; 140 Suppl. 54: 18-23
36. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000 Oct; 22: 1225-38
37. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001 Mar; 40: 210-2
38. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol 2001 Jan; 40: 64-6
39. Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 2002 Mar; 6: 95-102
40. Behrens S, Grundmann-Kollmann M, Peter RU, et al. Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid [letter]. Br J Dermatol 1999 Jul; 141: 177
41. Behrens S, Grundmann-Kollmann M, Schiener R, et al. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000 Mar; 42: 493-5
42. Koo JY, Lowe NJ, Lew-Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000 Nov; 43: 821-8
43. Schiener R, Behrens-Williams SC, Pillekamp H, et al. Calcipotriol vs tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis. Br J Dermatol 2000 Dec; 143: 1275-8
44. Tzaneva S, Honigsmann H, Tanew A, et al. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. Br J Dermatol 2002 Oct; 147: 748-53
45. Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 2002 Jun; 46: 907-13
46. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002; 3: 47-58
47. Kaidbey K, Kopper SC, Sefton J, et al. A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol 2001 Jul; 40: 468-71
48. Poulin YP. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis 1999 Jan; 63: 41-8
49. Abel EA. Phototherapy: UVB and PUVA. Cutis 1999 Nov; 64: 339-42
50. Koo JY. Tazarotene in combination with phototherapy. J Am Acad Dermatol 1998 Oct; 39: S144-8
51. Lowe NJ. Optimizing therapy: tazarotene in combination with phototherapy. Br J Dermatol 1999 Apr; 140 Suppl. 54: 8-11
52. Taylor CR, Stern RS, Leyden JJ, et al. Photoaging/photodamage and photoprotection. J Am Acad Dermatol 1990 Jan; 22: 1-15
53. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis: photochemotherapy follow-up study. Cancer 1994 Jun 1; 73: 2759-64
54. Jensen AM, Llado MB, Skov L, et al. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol 1998 Dec; 139: 984-91
55. Coynik D. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment. Cutis 2000 Dec; 66: 19-24
56. Hecker D, Worsley J, Yueh G, et al. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol 2000 Jun; 42: 1008-11
57. Leyden J, Lowe N, Kakita L, et al. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001 Jun; 67: 10-6
58. Bershad S, Kranjac SG, Parente JE, et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002 Apr; 138: 481-9
59. Veraldi S, Schianchi R. Short-contact therapy with tazarotene in psoriasis vulgaris. Dermatology 2003; 206: 347-8
60. Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998 May; 38: 705-11
61. Tzung TY, Wu JC, Hsu NJ, et al. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. Acta Derm Venereol 2005; 85: 236-9
62. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152 (4): 597-615
63. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999 Apr 8; 340: 1075-9
64. Lee E, Koo J. Single-center retrospective study of long-term use of low-dose acitretin (Soriatane) for psoriasis. J Dermatolog Treat 2004 Jan; 15: 8-13
65. Hotard RS, Feldman SR, Fleischer Jr AB. Sex-specific differences in the treatment of severe psoriasis. J Am Acad Dermatol 2000 Apr; 42: 620-3
66. Anstey A, Hawk JL. Isotretinoin-PUVA in women with psoriasis. Br J Dermatol 1997 May; 136: 798-9
67. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999 Sep; 41: S22-4